A Systematic Review of Safety and Immunogenicity of Influenza Vaccination Strategies in Solid Organ Transplant Recipients by Chong, P.P. et al.
A Systematic Review of Safety and Immunogenicity of 
Influenza Vaccination Strategies in Solid Organ Transplant 
Recipients
Pearlie P. Chong,1 Lara Handler,2 and David J. Weber3,4
1Division of Infectious Diseases, Department of Medicine, University of Texas Southwestern Medical Center, Dallas; 2Health Sciences Library and 3Division of Infectious Diseases, University of 
North Carolina, and 4Hospital Epidemiology, UNC Health Care, Chapel Hill, North Carolina
(See the Major Article by Natori et al on pages 1698–704.)
Immunogenicity from seasonal inactivated influenza vaccine (IIV) remains suboptimal in solid organ transplant recipients (SOTRs). 
We conducted a systematic review that compared the safety and immunogenicity of nonstandard influenza vaccination strategies 
with single-dose IIV in SOTRs. Booster doses and possibly high-dose (HD) influenza vaccination strategies seem to hold promise 
for improving vaccination immunogenicity in SOTRs. Administration of intradermal and MF59-adjuvanted trivalent IIV (IIV3) did 
not improve vaccine immunogenicity compared with single-dose intramuscular IIV. Alternative vaccine strategies were generally 
well tolerated; SOTRs who received HD, intradermal or adjuvanted IIV3 had a higher frequency of infection site reactions, while 
systemic adverse events were more frequent in SOTRs who received HD IIV3. Allograft rejection rates were similar in both groups. 
SOTRs should continue to receive standard-dose IIV annually in accordance with current recommendations, pending future studies 
to determine the optimal timing, frequency, and dosage of IIV using the booster-dose strategy.
Keywords. influenza vaccination; solid organ transplants; immunogenicity; immunization.
Influenza is an acute respiratory infection with a disease spec-
trum that ranges from a self-limited febrile illness to a highly 
severe disease, accounting for up to 49 000 deaths annually 
in the United States [1]. Immunocompromised individu-
als, including solid organ transplant recipients (SOTRs), are 
among those at highest risk for influenza-associated complica-
tions, such as allograft rejection and secondary bacterial pneu-
monia [2, 3].
The Centers for Disease Control and Prevention recommends 
use of annual influenza vaccination to reduce influenza-associ-
ated complications [4]. In SOTRs, immunological responses to 
influenza vaccination tend to be lower and more heterogene-
ous than in immunocompetent hosts, with seroprotection rates 
ranging from 15% to 90% [5–8]. Owing to the high likelihood 
of inadequate seroresponse secondary to intensified immuno-
suppression in the early posttransplantation period, the 2013 
Infectious Diseases Society of America Clinical Practice guide-
line vaccinating immunocompromised hosts recommends 
annual administration of inactivated influenza vaccine (IIV) 
>2  months after transplantation (strong, low recommenda-
tion), except when influenza outbreaks occur, during which IIV 
should be offered and administered as early as 1  month after
transplantation (weak, very low) [9].
Because influenza-associated complications continue to be an 
important cause of hospitalizations and deaths in SOTRs [10], 
various strategies such as high-dose (HD) influenza vaccines, a 
booster-dose (BD) strategy, intradermal vaccination, and adju-
vanted vaccines have been used. However, it remains unclear 
whether these alternative strategies improve immunogenicity 
over the standard approach (single standard dose [SD], intramus-
cularly administered IIV) in SOTRs. Understanding available data 
on the safety and immunogenicity of these nonstandard influ-
enza vaccination strategies may help clinicians make informed 
decisions about which strategy to undertake. We conducted this 
systematic review to evaluate and synthesize current evidence to 
address our primary question of whether alternative influenza 
vaccination strategies are (1) more immunogenic and (2) as safe 
as the standard single-dose intramuscular IIV in SOTRs.
METHODS
Search Strategy
With the assistance of an experienced medical librarian, 
MEDLINE (1946 through June 2017)  and EMBASE (1947 
through June 2017)  were searched, using a combination of 
search terms that included “influenza vaccine(s),” “flu shot,” 
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“flu vaccine,” “influenza vaccination,” and “flu vaccination,” 
combined with “transplants,” “transplant,” “graft(s),” “trans-
plant recipients,” and “organ transplantation.” The reference lists 
of selected articles were also searched for potentially eligible 
studies.
Study Selection and Extraction
Two investigators (P .P. C and D.  J. W) developed eligibility 
criteria a priori using PICOTS (population, intervention, com-
parison, outcome[s], and study design) criteria. Our study 
population consisted of adult and pediatric SOTRs, defined 
as recipients of heart, lung, liver, kidney, pancreas, intestinal, 
or multivisceral transplants, alone or in combination. Studies 
performed in hematopoietic stem cell transplant recipients 
and other immunocompromised hosts, such as patients with 
rheumatologic diseases and human immunodeficiency virus 
infection, were excluded. Any alternative (nonstandard) influ-
enza vaccination approach, predefined as use of intradermal or 
HD influenza vaccine, SD influenza vaccine administered more 
than once per season (BD strategy), and/or use of adjuvanted 
influenza vaccine was considered an intervention. 
Studies were included only if they compared the safety and 
immunogenicity of alternative influenza vaccination approaches 
with that of single SD intramuscular trivalent IIV (IIV3) in adult 
and/or pediatric SOTRs. All studies that included a compara-
tor group were eligible for inclusion, regardless of whether they 
were randomized controlled trials. Vaccine immunogenicity 
was defined based on the international European Agency for the 
Evaluation of Medicinal Products/Committee for Proprietary 
Medicinal Products 1997 criteria [11] and may include ≥1 of 
the following: (1) seroprotection rate, defined as the propor-
tion of individuals achieving titers ≥1:40; (2) seroconversion 
rate, defined as postvaccination titers >1:40 if prevaccination 
serum was negative or ≥4-fold increase in antibody titers if it 
was positive; and (3) geometric mean titer (GMT), defined as 
the mean postvaccination antibody titer. Studies published in 
non-English languages and those with only abstracts available 
were excluded.
Two independent reviewers (P. P.  C and D.  J. W) reviewed 
the title and abstract search, with inclusion decisions for each 
article made independently based on inclusion and exclusion 
criteria. Any discrepancies were resolved by consensus after a 
full-text review by both reviewers. Data extraction for eligible 
studies was conducted independently, focusing on the safety 
and immunogenicity of various alternative influenza vaccin-
ation strategies.
RESULTS
Study Range and Characteristics
The initial search yielded 1950 articles/abstracts (1372 arti-
cles/abstracts from EMBASE and 578 articles/abstracts from 
MEDLINE) (Figure  1). Of those, 428 were duplicates and 
excluded. After titles and abstracts of the remaining 1522 publi-
cations were screened, 17 articles were retrieved in full text and 
7 studies met eligibility criteria. Reasons for exclusion include 
lack of (n = 4) [12–15] or non-SOTR (n = 2) [16, 17] comparator 
group, heterogeneous patient population including patients with 
rheumatologic disease and human immunodeficiency virus 
infection (n  =  2) [18, 19], concerns regarding study methods 
(n = 1) [20], and duplicate trial results (n = 1) [21] (Figure 1).
Table 1 summarizes characteristics of the 7 selected studies, 
including 6 randomized controlled trials [22–27] and 1 pro-
spective cohort study [28]. Alternative influenza vaccination 
strategies evaluated in these studies included HD IIV3 [23] 
(n = 1), BD intramuscular IIV3 [24, 28] (n = 2), intradermal 
IIV3 [22, 26, 27] (n = 3), and adjuvanted IIV3 [25] (n = 1). All 
studies included SOTRs who received SD intramuscular IIV3 as 
a comparator group.
Patient Demographics and Inclusion/Exclusion Criteria
The 7 selected studies yielded a total of 943 patients (Table 1). 
Of these, 92% (868 of 943) were adult SOTRs, and 30% (279 of 
943) were female. Transplant types included kidney (n = 422),
liver (n = 229), lung (n = 181), heart (n = 89), intestinal (n = 1),
and multiorgan transplants (n  =  21). Most studies included
SOTRs ≥3  months after transplantation (5 of 7 studies) and
excluded those with a recent history of allograft rejection (5 of 7 
studies) and those with a documented history of severe adverse
reactions to influenza vaccination (4 of 7 studies).
Influenza Vaccine Characteristics and Vaccination Strategy
The alternative influenza vaccination strategy used differed 
across all 7 studies. GiaQuinta et al [23] investigated the effects 






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































of HD IIV3 containing 60  µg of antigen per influenza virus 
strain; Kumar et al [25] evaluated an MF59-adjuvanted vaccine 
that contained 15 µg of antigen per strain. Studies that investi-
gated the use of intradermal IIV3 used 6 µg of antigen per strain 
administered simultaneously in 2 doses (cumulatively, 12 µg of 
antigen per strain) [27], 9 µg of antigen per strain administered 
simultaneously in 2 doses (cumulatively, 18 µg of antigen per 
strain) [22] and 15 µg of antigen per strain in a single dose [26]. 
Cordero et al [24]. and Hojsak et al [28] evaluated BD strategies 
in which 2 sequential doses of SD IIV3 were administered 5 or 
4–6 weeks apart, respectively.
The comparator group in all studies consisted of SOTRs 
who received SD IIV3 containing 15 µg of antigen of each of 2 
A (H1N1 and H3N2) strains and 1 B strain of influenza given as a 
single 0.5-mL intramuscular dose. Selection of vaccine strains was 
dependent on the annual recommendations by the World Health 
Organization based on circulating influenza strains (Table 1).
Vaccination Immunogenicity
All 7 studies assessed for vaccination immunogenicity by meas-
uring pre- and postvaccination strain-specific influenza antigen 
titers using hemagglutination inhibition assay (Table  2). The 
timing of serum sample collection varied, most commonly 4 
weeks after vaccination but ranging between 3 [26] to 6 weeks 
after vaccination [23, 28]. Most studies (86%; 6 of 7) included 
seroconversion rate, seroprotection rate and differences in pre- 
and postvaccination GMT as measures of vaccine immunogen-
icity. Short-term immunogenicity was assessed in all studies; 
long-term immunogenicity at 12 months after vaccination was 
evaluated in 1 study [24].
Intradermal Influenza Vaccine
Using a 2-dose simultaneous administration strategy, serocon-
version rates to ≥1 influenza antigen did not differ between 
intradermal and intramuscular groups (48.2% [55 of  114] vs 
42.6% [49 of 115; P =  .47] [22] and 14.6% [6 of 41] vs 18.6% 
[8 of 43; P =  .77] [27]). In addition, pre- and postvaccination 
GMT and seroprotection rates were also not different [22, 27]. 
Baluch et al [22] noted a trend toward higher postvaccination 
GMT (41.31 vs 29.1; P = .07) and seroprotection rate (63.6% vs 
52.4%; P = .10) for influenza B in the intradermal group, but the 
differences was not significant. Manuel et al [27] reported sig-
nificantly lower seroprotection rates for A/H3N2 (83% vs 98%; 
P = .02) and influenza B (29% vs 58%; P < .01) in the intrader-
mal group compared with the comparator group.
Morelon et al [26] reported higher seroconversion rates for 
influenza A/H1N1 (35% [11 of  31] vs 19% [6 of  31]) and A/
H3N2 (35% [11 of 31] vs 19% [6 of 31]) but not influenza B (19% 
[6 of 31 vs 19% [6 of 31]) in the intradermal group. Similarly, 
seroprotection rates were higher for influenza A/H1N1 (71% 
[22 of 31] vs 52% [16 of 31]), A/H3N2 (52% [16 of 31] vs 36% 
[11 of 31]) and similar for influenza B (71% [22 of 31] vs 61% 
[19 of 31]) in the intradermal group. Postvaccination GMT was 
higher for influenza A/H1N1 in the intradermal group than in 
the comparator group (95.7% vs 44.7%); these values were sim-
ilar in the 2 groups for A/H3N2 (38.3% vs 25.3%, respectively) 
and influenza B (48.4% vs 41.4%) [26].
Baluch et al [22] analyzed factors that influenced seroprotec-
tion. SOTRs receiving ≥2 g/d of mycophenolate mofetil (MMF) 
(37.3% vs 62.7%; P  =  .02), lung transplant recipients (28% vs 
72%; P =  .02), and those <6 months after transplantation (8.7% 
vs 91.3%; P  =  .01) had a significantly lower seroprotection rate 
for A/H1N1. Patients receiving ≥2 g/d of MMF (36.6% vs 63.4%; 
P = .04) and those <6 months after transplantation (6.5% vs 93.5%; 
P < .01) also had lower seroprotection rates for influenza B [22].
HD Influenza Vaccine
In the study by GiaQuinta et al [23], 38 pediatric SOTRs were 
randomized to either HD or SD IIV3. Seroconversion for A/
H3N2 occurred in a higher proportion of the HD group com-
pared with the SD group (54% vs 13%; P =  .01) [23], but the 
seroprotection rate for A/H1N1 (95% vs 80%; P = .14) and in-
fluenza B (46% vs 47%; P = .94) and postvaccination GMTs for 
A/H1N1 (GMT difference, 462.9; 95% confidence interval [CI], 
−85.9 to 1112.4) did not differ between the 2 groups [23].
BD Influenza Vaccine
Cordero et al [24] reported the results of the TRANSGRIPE 1-2 
study, an open-label, phase 3, parallel-group, randomized con-
trolled clinical trial that evaluated the safety and efficacy of a BD 
administered 5 weeks after an initial dose of IIV3 compared with 
the single SD intramuscular nonajuvanted IIV3 in SOTRs. Using 
modified intention-to-treat (mITT) analysis, 2 doses of influenza 
vaccine was associated with a higher seroconversion rate for influ-
enza A(H1N1)pdm at 10 weeks using bivariable analyses (46.7% vs 
32.7%; odds ratio [OR], 1.81; 95% CI, 1.01–3.24; P = .05) but not to 
other influenza strains, or after adjustment for potential confound-
ers in multivariable analyses. In the per-protocol analysis, a BD 
of IIV3 was independently associated with a higher likelihood of 
seroconversion at 10 weeks for all influenza strains, with the num-
ber needed to treat to achieve seroconversion being 7 [24].
Seroprotection rate was higher in the BD than in the control 
group using mITT, for the 3 types of influenza virus: 54% versus 
43.2% (OR, 1.54; 95% CI, 1.05–2.27; P = .03) for A(H1N1)pdm; 
56.9% versus 45.5% (OR, 1.58; 95% CI, 1.08–2.31; P = .02) for 
A(H3N2); and 83.4% versus 71.8% (OR, 1.97; 95% CI, 1.23–
3.16; P < .01) for influenza B. A booster IIV3 dose was inde-
pendently associated with higher seroprotection rates, with the 
number needed to treat to achieve seroprotection being ≤10 
for all 3 strains. Short-term postvaccination GMTs were signif-
icantly higher in the BD group than in the control group, an 
effect observed only in bivariable analysis in both the mITT 
and per-protocol analyses but not the multivariable analyses 
and only for influenza A/H3N2 and influenza B. At 1 year after 
Table 2. Summary of Vaccine Immunogenicity
Study Immunogenicity Marker Intervention Groupa Comparator Groupa P Valueb
Baluch et al [22] A/H1N1 HD SD
Seroprotection ratec 71 (76/107) 70.5 (74/105) .93
Seroconversion rated 37.4 (40/107) 34.3 (36/105) .64
Prevaccination GMT 24.0 (18.2–31.6) 22.1 (16.7–29.3) .61
Postvaccination GMT 68.9 (50.4–94.3) 62.2 (45.7–84.9)




Seroprotection rate 70.1 (75/107) 63.8 (67/105) .33
Seroconversion rate 29 (31/107) 30.5 (32/105) .81
Prevaccination GMT 21.9 (17–26.7) 19.7 (15.9–24.6) .48
Postvaccination GMT 51.1 (40.2–64.8) 43.6 (33.5–56.7)




Seroprotection rate 63.6 (68/107) 52.4 (55/105) .10
Seroconversion rate 21.5 (23/107) 17.1 (18/105) .42
Prevaccination GMT 18.6 (14.4–24) 17.0 (13.4–21.5) .07
Postvaccination GMT 41.41 (31.8–53.6) 29.1 (22.3–38)
Geometric mean seroconversion 
factore
2.22 1.72 .42
GiaQuinta et al [23] A/H1N1 HD SD
Seroprotection rate 95.5 (21/22) 80 (12/15) .14
Seroconversion rate 68 (15/22) 47 (7/15) .19
Prevaccination GMT 77.5 (35.2–170.5) 62 (20.9–155.1) NA
Postvaccination GMT 773.2 (374.6–1363.3) 310.3 (124–718.4) NA
GMT difference estimate 695.7 (305.3–1299.2) 248.3 (32.9–681.9) NA
A/H3N2 HD SD
Seroprotection rate 86 (19/22) 80 (12/15) .61
Seroconversion rate 54 (12/22) 13 (2/15) .01
Prevaccination GMT 34.7 (21–55.7) 93.3 (47.4–195.5) NA
Postvaccination GMT 131.7 (76.7–233.5) 136.1 (71.8–254) NA
GMT difference estimate 97 (35.8–194) 42.8 (−64.4 to 170.5) NA
B HD SD
Seroprotection rate 46 (10/22) 47 (7/15) .94
Seroconversion rate 18 (4/22) 33 (5/15) .29
Prevaccination GMT 19.6 (14.2–26.8) 21.1 (11.4–48.9) NA
Postvaccination GMT 36.8 (23.3–60.6) 36.2 (18.9–83.2) NA
GMT difference estimate 17.2 (1.9–42.4) 15.1 (−15.4 to 62.1) NA
Cordero et al [24] Short-termf
A/H1N1 BD Single SD OR (95% CI)
  Seroprotection rate 54 (114/211) 43.2 (92/213) 1.54 (1.05–2.27)
  Seroconversion rate 46.7 (43/211) 32.7 (33/213) 1.81 (1.009–3.24)
  Postvaccination GMT 41.61 (32.90–52.61) 33.34 (25.45–43.67) 0.06 (−.01 to 
0.04)
 A/H3N2 BD Single SD OR (95% CI)
  Seroprotection rate 56.9 (120/211) 45.5 (97/213) 1.58 (1.08–2.31)
  Seroconversion rate 39.1 (45/211) 30.2 (38/213) 1.49 (.87–2.54)
  Postvaccination GMT 44.73 (35.16–56.85) 27.16 (21.43–34.41) 0.14 (.01–.07)
B BD Single SD
  Seroprotection rate 83.4 (176/211) 71.8 (153/213) 1.97 (1.23–3.16)
  Seroconversion rate 75.9 (63/211) 63.9 (53/213) 1.78 (.91–3.50)
  Postvaccination GMT 180.08 (139.45–232.57) 95.31 (71.91–126.32) 0.16 (.02–.06)
Long-termf
 A/H1N1 BD Single SD OR (95% CI)
  Seroprotection rate 27 (57/211) 33.3 (71/213) 0.74 (.49–1.12)
  Seroconversion rate 20.7 (19/211) 19.8 (20/213) 1.05 (.52–2.13)
Study Immunogenicity Marker Intervention Groupa Comparator Groupa P Valueb
  Postvaccination GMT 15.94 (13.33–19.07) 17.48 (14.40–21.22) −0.03 (−.05 to 
.02)
 A/H3N2 BD Single SD OR (95% CI)
  Seroprotection rate 48.3 (102/211) 53.5 (114/213) 0.81 (.56–1.19)
  Seroconversion rate 40.9 (47/211) 45.2 (57/213) 0.84 (.50–1.40)
  Postvaccination GMT 42.58 (32.69–55.45) 46.46 (35.61–60.62) −0.02 (−.03 to 
.02)
B BD Single SD OR (95% CI)
  Seroprotection rate 73.5 (155/211) 69 (135/213) 1.24 (.89–1.89)
  Seroconversion rate 63.9 (53/211) 50.6 (42/213) 1.73 (.91–3.50)
  Postvaccination GMT 77.67 (61.09–98.75) 69.55 (54.53–88.71) 0.03 (−.02 to 
.04)
Hojsak et al [28] A/H1N1 BD Single SD …
Seroprotection rate (baseline) 48 (18/37) 58.8 (10/17)
Seroprotection rate (1 dose) 64.9 (24/37) (P = .08)g 64.7 (11/17) (P = .33)
Seroprotection rate (2 doses) 75 (27/32) (P = .005) NA
Seroconversion rate (1 dose) 40.5 (15/37) 17.6 (3/17)
Seroconversion rate (2 doses) 54.0 (20/37) NA
GMT (t1) 31.35 47.08
GMT (t2) 67.59 (P = .37) 65.25 (P = .09)
GMT (t3) 80.00 (P = .001) NA
A/H3N2
Seroprotection rate (baseline) 43.2 (16/37) 16.7 (3/18)
Seroprotection rate (1 dose) 70.3 (26/37) (P = .003) 47.1 (8/17) (P = .06)
Seroprotection rate (2 doses) 84.4 (27/32) (P ≤ .001) NA
Seroconversion rate (1 dose) 35.1 (13/37) 42.2 (7/17)
Seroconversion rate (2 doses) 56.7 (21/37) NA
GMT (t1) 39.26 12.6
GMT (t2) 89.52 (P = .028) 33.00 (P = .03)
GMT (t3) 103.75 (P = .001) NA
B
Seroprotection rate (baseline) 8.1 (3/37) 50 (9/18)
Seroprotection rate (1 dose) 35.1 (13/37) (P = .003) 58.8 (10/17) (P = .58)
Seroprotection rate (2 doses) 35.5 (11/32) (P = .009) NA
Seroconversion rate (1 dose) 40.5 (15/37) 16.7 (3/18)
Seroconversion rate (2 doses) 48.6 (18/37) NA
GMT (t1) 7.99 46.6
GMT (t2) 24.12 (P < .001) 69.48 (P = .13)
GMT (t3) 21.3 (P < .001) NA




Seroprotection rate 83.9% 86.2% .80
Seroconversion rate 45.2% 48.3% .28
Prevaccination GMT 31.3 28.6 .77
Postvaccination GMT 136.8 123.0 .65
Seroconversion factor 4.37 4.30 .73
A/H3N2
Seroprotection rate 100% 93.1% .23
Seroconversion rate 48.4% 34.5% .28
Prevaccination GMT 62.6 71.0 .86
Postvaccination GMT 209.2 184.7 .96
Seroconversion factor 3.34 2.60 .56
B
Seroprotection rate 61.3% 65.5% .73
Seroconversion rate 32.3% 24.1% .49
Prevaccination GMT 28.6 22.0 .36
Postvaccination GMT 71.5 48.4 .33
Seroconversion factor 2.50 2.20 .98
Table 2. Continued
vaccination, no differences in rates of seroconversion, seropro-
tection, and GMTs were observed between treatment groups. 
In a prospective cohort study performed in pediatric 
liver transplant recipients (n = 37), Hojsak et al [28] reported 
higher seroprotection rates after 2 sequential SDs of the 
intramuscular IIV3, 4–6 weeks apart during the 2005–2006 
influenza season for all 3 strains compared with baseline, as 
follows: A/H1N1, 
75% versus 48.6% (P = .005); A/H3N2, 84.4% versus 43.2% (P 
≤ .001); and B, 35.5% versus 8.1% (P < .01). Seroprotection rates 
for the group that received single SD intramuscular IIV3 dur-
ing the 2004–2005 influenza season were as follows, again com-
pared with baseline seroprotection rates: A/H1N1, 64.7% versus 
58.8% (P = .33); A/H3N2, 47.1% versus 16.7% (P = .06); and B, 
58.8% versus 50% (P = .58).
Study Immunogenicity Marker Intervention Groupa Comparator Groupa P Valueb
Morelon et al [26] A/H1N1 SD, intradermal, 1 dose SD IIV3, intramuscular or subcu-
taneous, 1 dose
NAi 
Seroprotection rate 71 (22/31) 52 (16/31)
Seroconversion rate 35 (11/31) 19 (6/31)
Prevaccination GMT 30.9 (18.9–50.6) 23.1 (13.5–39.7)
Postvaccination GMT 95.7 (55.1–166) 44.7 (24.3–82.4)
 GMTR 3.09 (2.17–4.40) 1.93 (1.30–2.88)
A/H3N2
Seroprotection rate 52 (16/31) 36 (11/31)
Seroconversion rate 35 (11/31) 19 (6/31)
Prevaccination GMT 10.9 (0.8–21.4) 10.8 (8.66–13.5)
Postvaccination GMT 38.3 (25–58.5) 25.3 (15.8–40.4)
 GMTR 3.50 (2.29–5.34) 2.34 (1.56–3.51)
B
Seroprotection rate 71 (22/31) 61 (19/31)
Seroconversion rate 19 (6/31) 19 (6/31)
Prevaccination GMT 24.7 (18.5–33.0) 23.4 (16.1–33.9)
Postvaccination GMT 48.4 (34.7–67.4) 41.4 (27.8–61.4)
 GMTR 1.96 (1.57–2.44) 1.77 (1.38–2.27)
Manuel et al [27] A/H1N1 SD, intradermal, 2 simultane-
ous doses
SD IIV3, intramuscular, 1 dose
Seroprotection rate 39 (16/41) 28 (12/43) .36
Seroconversion rate 7.3 (3/41) 7 (3/43) >.99
Prevaccination GMT 12.3 (8.8–17.1) 12.0 (8.8–16.4) .91
Postvaccination GMT 15.7 (11.1–22.3) 17.5 (11.8–25.9)
Seroconversion factor 1.3 (1.0–1.6) 1.5 (1.2–1.9) .15
A/H3N2
Seroprotection rate 83 (16/41) 98 (42/43) .02
Seroconversion rate 4.9 (2/41) 7 (3/43) >.99
Prevaccination GMT 74.6 (47.3–117.6) 83.0 (61.8–111.6) .60
Postvaccination GMT 84.0 (52.0–135.7) 108.9 (77.5–153.2)
Seroconversion factor 1.1 (0.98–1.3) 1.3 (1.1–1.6) .24
B
Seroprotection rate 29 (12/41) 58 (12/43) .36
Seroconversion rate 7.3 (3/41) 11.6 (5/43) .71
Prevaccination GMT 11.5 (7.6–17.4) 14.1 (9.3–21.3) .28
Postvaccination GMT 14.5 (9.6–21.8) 20.2 (12.8–31.9)
Seroconversion factor 1.3 (1.1–1.5) 1.4 (1.0–1.9) .65
Abbreviations: BD, booster dose; CI, confidence interval; GMT, geometric mean titer; GMT (t1), GMT at baseline,; GMT (t2), GMT after single-dose influenza vaccine; GMT (t3), GMT after 2 
doses of influenza vaccine; GMTR, GMT ratio; HD, high dose; IIV3, inactivated trivalent influenza vaccine; NA, not applicable; OR, odds ratio; SD, standard dose.
aUnless otherwise specified, values represent % (proportion) of patients for seroprotection and seroconversion rates and [mean? median?] (95% CI) for GMT, GMTR, and GMT difference.
bValues represent P values unless otherwise specified.
cSeroprotection rates are defined as the percentage of subjects achieving a hemagglutination inhibition titer ≥1:40.
dSeroconversion rates are defined as the percentage of subjects achieving ≥4-fold rise in titer from baseline.
eThe geometric mean seroconversion factor is defined as the ratio of GMT between post- and prevaccination titers.
fResults presented are from intention-to-treat analysis.
gP values for Hojsak et al represent difference between immunogenicity marker after a single dose (or 2 doses) of influenza vaccine compared with baseline in the same study subject.
hProportions for rates and confidence intervals for GMTs were not provided by Kumar et al.
iMorelon et al used descriptive statistics; statistical testing not done, and P values were not available.
Table 2. Continued
Adjuvanted SD Influenza Vaccine
In a clinical trial of adult kidney transplant recipients randomized 
to receive either MF59-adjuvanted IIV3 or nonadjuvanted IIV3, 
the seroprotection and seroconversion rates and postvaccination 
GMTs did not differ between the 2 groups [25]. A subgroup ana-
lysis demonstrated that MF59-adjuvanted IIV3 was the only factor 
significantly associated with seroconversion (OR, 6.10; 95% CI, 
1.2 –28.6) [25]. Use of MMF at ≥2 g/d (44.4% vs 71.4%; P = .05) 
and older age (OR per year of increasing age, 0.95; 95% CI, .90–.99) 
were significantly associated with lower seroconversion rates [25]. 
Vaccine Safety
Intradermal Influenza Vaccine
The proportion  of local adverse events (AEs), such as erythema 
(P < .001), induration (P < .001), tenderness (P < .001), and pru-
ritus (P = .005), were significantly higher with intradermal IIV3 
[22, 26] (Table 3). Although Manuel et al [27] reported a higher 
percentage of local AEs, this difference was not statistically sig-
nificant (41% vs 25%; P = .16). Local AEs were mild or moder-
ate in severity, and their severity and duration did not different 
between the 2 groups.
Systemic AEs did not differ between the intradermal and com-
parator groups in the studies by Morelon et al (55% vs 52%) [26] and 
Manuel et al [27] (7% vs 16%; P = .31). Baluch et al [22] reported a 
higher frequency of nausea and diarrhea in the intradermal group. 
Allograft rejection rates within 6 months after vaccination also did 
not differ between the intradermal and comparator groups; graft 
function was stable in all patients at the time of follow-up in this 
study, and confirmed development of de novo anti-human leuko-
cyte antigen antibody was reported in only 1.4% (3 of 212) [22].
HD Influenza Vaccine
SOTRs who received HD IIV reported more injection site ten-
derness (73% vs 40%; P = .05), erythema (82% vs 47%; P = .02), 
myalgias (27% vs 0%; P = .03), and fatigue (23% vs 0%; P = .05) 
[23]. Allograft rejection occurred in 2.6% (1 of 38) 6 months 
after influenza vaccination in the SD group and thus was 
deemed unrelated [23].
BD Strategy
Rates of allograft rejection rates and local and systemic AEs did 
not differ significantly between the BD and comparator groups (P 
> .05) [24]. Most AEs reported were mild or moderate in severity.
Adjuvanted SD Influenza Vaccine
SOTRs who received the MF59-adjuvanted IIV3 were signifi-
cantly more likely to develop injection site tenderness than those 
who received nonadjuvanted intramuscular IIV3 (77.4% vs 51.6%; 
P = .03); other local and systemic AEs did not differ between the 2 
groups. Only 1 episode of acute allograft rejection was reported 3 
weeks after vaccination during the 6-month follow-up period, and 
this occurred in the nonadjuvanted vaccine group.
DISCUSSION
Despite alternative influenza vaccination strategies, seroconver-
sion and seroprotection rates for influenza antigens were low in 
SOTRs. Neither intradermal [22, 26, 27] nor adjuvanted [25] 
influenza vaccine strategies improved immunogenicity com-
pared with single SD intramuscular IIV3. Whereas HD and BD 
IIV3 conferred better seroprotection, antigen-specific immu-
nogenicity varied substantially across studies. Pediatric SOTRs 
who received HD IIV3 were more likely than those in the SD 
IIV3 group to seroconvert for A/H3N2, but not for A/H1N1 or 
influenza B. In the TRANSGRIPE 1-2 study, a booster IIV3 dose 
administered 5 weeks after the first dose was significantly asso-
ciated with a higher seroconversion rate for A/H1N1 but not for 
other strains [24]. The heterogeneity in influenza antigen-spe-
cific immunogenicity seems unpredictable and independent of 
the vaccination strategy. A prospective cohort study performed 
in pediatric liver transplant recipients reported significantly 
higher seroprotection rates for all 3 influenza strains after 2 
sequential SDs of the intramuscular IIV3, 4–6 weeks apart [28].
Among transplant types, lung transplant recipients had the 
lowest seroresponse rates to influenza vaccination. In add-
ition to ≥2 g/d of MMF and vaccination within 6 months after 
transplantation, Baluch et  al [22] found that lung transplant 
recipients had lower seroprotection rates to A/H1N1 and that 
intradermal influenza vaccine had greater immunogenicity in 
recipients of non-lung transplants in a subgroup analysis. In 
another study by Manuel et  al [27], seroconversion rates to 
each of the IIV3 influenza antigens in lung transplant recipients 
ranged from 5% to 12% . Limited data are available regarding 
long-term immunogenicity of alternative influenza vaccination 
strategies. In the TRANSGRIPE 1-2 study, the 1-year postvacci-
nation seroconversion, seroprotection rates and GMTs did not 
differ between the BD and SD groups. A decrease in the 1-year 
GMT was noted in both groups [24].
These nonstandard influenza vaccination strategies seem to 
be safe and generally well tolerated. SOTRs who received HD, 
intradermal, and adjuvanted IIV were more likely to experience 
local AEs, which were mild or moderate and transient injec-
tion site reactions. Systemic AEs were more frequent in SOTRs 
who received HD IIV3. Allograft rejection rates did not differ 
between the alternative and standard influenza vaccine groups.
There was substantial heterogeneity in the design, protocols, 
and data analyses of the included studies, some of which could 
have introduced bias. Morelon et al [26] prescreened and enrolled 
only adult renal transplant recipients who were vaccinated in the 
previous influenza season but failed to serorespond to A/H3N2. 
Enrolled patients were thus less likely to serorespond, possibly 
accounting for low seroconversion and seroprotection rates. 
This same study reported only descriptive statistics and did not 
perform statistical comparisons, so differences in vaccine immu-
nogenicity for each antigen are highly subject to interpretation. 
Hojsak et al [28] aimed to compare a 2-dose standard 
intramus-cular IIV3 with findings in pediatric liver transplant 
recipients who received single-dose intramuscular IIV3 in 
the previous 
influenza season, but statistical comparisons were not per-
formed between the 2 groups, limiting interpretation of the 
results. Finally, there was variability in postvaccination serum 
sample collection (ranging from 3 to 6 weeks after vaccina-
tion); it is unclear whether this variability contributed to vaccine 
immunogenicity differences across studies.
In conclusion, BD and HD influenza vaccination strategies 
seem to hold promise for improving vaccination immunogenic-
ity and were generally well tolerated in SOTRs. Future studies 
should focus on clarifying the optimal timing, frequency, and 
dose and in assessing whether these strategies improve vac-
cine immunogenicity. In the interim, SOTRs should continue 
to receive the SD IIV annually in accordance with current 
Infectious Diseases Society of America and Centers for Disease 
Control and Prevention recommendations.
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